title: A potential antitumor peptide therapeutic derived from antineoplastic urinary protein.
abstract: New therapies in cancer treatment are focusing on multifaceted approaches to starve and kill tumors utilizing both antiangiogenic and chemotherapeutic compounds. Antineoplastic Urinary Protein (ANUP), a 32k Da protein normally secreted in human urine, has been previously described as a molecule possessing both antiproliferative and antiangiogenic activities. Two synthetic peptides complimentary to the N-terminus of ANUP were designed to test their ability to reproduce these beneficial effects but ultimately to provide a more useful small molecule therapeutic. The results show that the peptides reduced tumor burden by up to 70% in a nude mouse model and demonstrated the ability to inhibit blood vessel formation in a chick chorioallantoic membrane assay (CAM).
authors.affiliation: TranXenoGen Inc., Technology Development, 800 Boston Turnpike, Shrewsbury, MA 01545, USA. khehir@tranxenogen.com
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Hehir
authors.forename: Alexander
authors.initials: A
authors.lastname: Baguisi
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Pennington
authors.forename: Janna M
authors.initials: JM
authors.lastname: Bates
authors.forename: Paul A
authors.initials: PA
authors.lastname: DiTullio
mesh_terms: D000818:Animals; D000950:Antigens, Ly / Q000008:administration & dosage*; D002642:Chick Embryo; D017281:Cost of Illness; D005260:Female; D006367:HeLa Cells; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology; D010455:Peptides / Q000008:administration & dosage*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D000950:Antigens, Ly; D010455:Peptides; C048963:SLURP1 protein, human; D014568:Urokinase-Type Plasminogen Activator